Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.
Develops gene and cell therapies including an approved treatment for recurrent respiratory papillomatosis.
Its first product, Papzimeos, treats recurrent respiratory papillomatosis, a rare condition where wart-like growths block the airways, and is sold to specialist hospitals. Before approval it lived on licensing deals and shares sold to investors. Randal Kirk's Third Security has long been the largest shareholder.
Moat: none (IP / patents, regulatory licence). First mover with an approved rare-disease gene therapy, but a thin, still-loss-making commercial base.
Headquarters: Germantown, Maryland, US · Founded: 1998 · Employees: 160
Size Precigen (PGEN) is a United States Health Care company (Biotechnology) with a market value of $1.53B, the 1960th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.27 on 18 Nov 2026.
Performance Over six months the shares was unchanged, against -12.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 2,387.6% over the last twelve months (peer median +25.4%); the operating margin is 21.4% (peer median -5.7%).
Valuation It trades at 7.3× forward earnings against a peer median of 37.0× (cheapest of 9).
Capital Return on invested capital runs 9.6 points above its cost of capital (9.9% WACC).
Short interest Short interest is 12.5% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $157M | $9.68M | $3.92M | $6.22M | $26.9M |
| Revenue growth | — | +147% | -37% | -77% | — |
| Gross profit | $142M | $3.59M | -$3.40M | -$4.74M | $15.8M |
| EBITDA | $38.1M | -$103M | -$90.2M | -$82.3M | -$67.4M |
| Net income | $24.4M | -$251M | -$126M | -$95.9M | -$66.4M |
| Free cash flow | -$74.3M | -$89.8M | -$76.8M | -$68.5M | -$70.0M |
| Capital expenditure | $1.10M | $2.00M | $8.58M | $1.54M | $4.92M |
| Total debt | $98.6M | $98.3M | $5.50M | $7.10M | $51.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Precigen PGEN | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a |
| Ultragenyx Pharmaceutical RARE | $1.81B | -24% | +16% | -64% | 9.6× | n/a |
| PTC Therapeutics PTCT | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% |
| Intellia Therapeutics NTLA | $1.37B | -20% | -8% | -821% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGEN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -37.5% | -10.9% | 2nd lowest of 21 |
| 6-month return | 0.0% | -12.8% | 7th highest of 20 |
| Distance from 52-week high | -52.5% | -44.5% | 6th lowest of 21 |
| Revenue growth (TTM) | +2,387.6% | +25.4% | highest of 19 |
| Operating margin | 21.4% | -5.7% | 4th highest of 19 |
| Forward P/E | 7.3× | 37.0× | cheapest of 9 |
| ROIC minus cost of capital | +9.6 pp | -11.0 pp | highest of 15 |
| EV / EBITDA | 41.6× | 13.5× | most expensive of 5 |
| Net debt / EBITDA | 1.4× | 0.7× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |